Quantcast
Last updated on April 16, 2014 at 4:43 EDT

Latest Orphan drug Stories

2013-10-08 23:21:59

Report uncovers results and trends unavailable from any other news service and before pharmaceutical company disclosures; webinar speakers include former director of FDA’s Office of Orphan Drugs. Norwood, MA (PRWEB) October 08, 2013 BioPharm Insight™ is emphasizing orphan drug development this month with an exclusive subscriber report on the orphan drug market base and an educational webinar on the topic. BioPharm Insight – which is part of Infinata, a Financial Times Group company...

2013-10-07 08:25:49

Makovsky Health VP Bernstein Presents at 2013 DIA-NORD Conference in Bethesda, MD, October 7-9 NEW YORK, Oct. 7, 2013 /PRNewswire/ -- New health economics research assessing the current impact of the Orphan Drug Act (ODA) suggests the law continues to play a crucial role in stimulating drug development for small patient populations. The descriptive study is presented this week as a poster at the 3(rd) Annual DIA-NORD Conference on Rare Diseases & Orphan Products in Bethesda, MD....

2013-10-04 04:20:23

STOCKHOLM, October 4, 2013 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces it has raised SEK96 million (EUR11m / US$15m) in a Series C financing round. The round was co-led by two of the Nordic region's largest venture investors: Investinor, which is a new investor in Pharmalink, and Industrifonden, a current investor. Other existing investors also participated. The new funds will be used to:...

2013-10-02 23:01:39

Despite federal incentives for drug companies to create treatments for rare diseases, thousands of people are still searching for lifesaving therapies. In many cases, patients and those working on their behalf are taking matters into their own hands. Bethesda, MD (PRWEB) October 02, 2013 Katheryn Elibri, whose 7-year-old daughter has a rare genetic disease known as CDKL5 and has seizures almost daily, helped begin a foundation to fund research for a cure. Other parents—like Lisa Schill,...

2013-09-30 23:18:18

The Rare Disease Panel will present on October 7, 2013 at 9:45 a.m. Bethesda, MD (PRWEB) September 30, 2013 WHAT: Thirty years after the adoption of the Orphan Drug Act, patients with rare diseases still face incredible obstacles. At the U.S. Conference on Rare Diseases and Orphan Products, with its theme of “The New Era in Health Care,” patients and patient advocates will discuss: Getting an accurate diagnosis Supporting research for and the development of treatments Assuring...

2013-09-30 08:28:47

-- Phase 2 Clinical Trial in Huntington's Disease Slated to Begin This Year -- SEATTLE, Sept. 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including...

2013-09-26 23:31:37

MarketResearchReports.Biz announces addition of new report “Orphan Drugs Market in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/orphan-drugs-in-europe-pricing-reimbursement-funding-and-market-access-issues-2013-edition Albany, NY (PRWEB) September 26, 2013 The cost of treating rare diseases in an age when austerity measures are hitting a total health care funding across Europe is a...

2013-09-26 23:19:52

Reportbuyer.com just published a new market research report: Orphan Drugs for Cancer: R&D and Market 2013-2023. London (PRWEB) September 26, 2013 Report Details Orphan cancer drugs - new study shows you trends, R&D, and sales forecasts What's the future of orphan medicines to treat cancers? Visiongain's new report gives you revenue predictions from 2013. There you explore results, R&D, opportunities, and potential sales. Orphan drugs can be profitable. In our analysis...

2013-09-23 12:26:42

NextSource Biotechnology Re-Introduces Critical Oncology Medication avoiding major losses in the Healthcare Sector MIAMI, Sept. 23, 2013 /PRNewswire/ -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing company with a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and International Healthcare Markets. By utilizing a worldwide distribution network as a key...

2013-09-13 23:01:19

Register Now to Attend Premier Conference on Orphan Product Development, Emerging Markets and Outlook for Investment. Horsham, PA (PRWEB) September 13, 2013 The early registration deadline for the third annual U.S. Conference on Rare Diseases and Orphan Products is Monday, Sept. 16. Co-sponsored by the National Organization for Rare Disorders (NORD) and DIA in collaboration with the Food and Drug Administration (FDA) and EURORDIS (Rare Diseases Europe), the conference will take place from...